



ASX Release

12 February 2019

ZELDA THERAPEUTICS LIMITED
ACN 103 782 378

Level 26
140 St Georges Terrace,
Perth Western Australia 6000
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeldatherapeutics.com
W: www.zeldatherapeutics.com

Contacts

Dr Richard Hopkins
Managing Director
+61 405 656 868
rhopkins@zeldatherapeutics.com

Monsoon Communications
Rudi Michelson
+61 3 9620 3333
rudym@monsoon.com

Directors

Dr Richard Hopkins
Mr Harry Karelis
Dr Stewart Washer
Ms Mara Gordon
Mr Jason Peterson

Tickers:

Australia (ASX): ZLD
USA (OTCQB): ZLDAF

Ordinary Shares:

755,341,934

Options:

60,700,000

Zelda Engages International Cannabis and Cannabinoids Institute for Clinical Trial and Regulatory Expertise

- Provides opportunity to collaborate with leading international cannabis expert Dr Ethan Russo, a global leader in development of cannabis-based medicines
- Engagement brings together world-leading medical advisory team

Zelda Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF) has engaged the International Cannabis and Cannabinoids Institute (ICCI) to support the Company's clinical trial programmes in autism, opioid reduction and insomnia.

The ICCI is an international Centre of Excellence for the advancement of cannabis and cannabinoid treatments. The ICCI provides access to a global network of specialist services including expert advice on clinical study design and execution, requirements for regulatory approval, a full range of contract research services and direct liaison with study investigators.

This agreement provides Zelda with an opportunity to collaborate with a panel of leading international medicinal cannabis experts including Dr Ethan Russo, who was recently appointed the Director of Research and Development at the ICCI.

Dr Ethan Russo, MD, is a US-trained board-certified paediatric and adult neurologist, psychopharmacology researcher, former Senior Medical Advisor to GW Pharmaceuticals, and Medical Director of PHYTECS. He served as study physician to GW Pharmaceuticals for numerous Phase I-III clinical trials of Sativex®, and early stage investigations of Epidiolex®. He is author/editor of seven books on cannabis and medicinal herbs, and has also published numerous book chapters, and over 50 articles in neurology, pain management, cannabis and ethnobotany.

Zelda's Managing Director, Dr Richard Hopkins, commented "We're honoured to be working with the ICCI and Dr Ethan Russo, who are recognised globally as leading authorities on medicinal cannabis. Their insights will help inform and accelerate our clinical trial programmes.

Dr Russo and the ICCI will complement our existing medical advisory team and maintains Zelda's strategy of engaging the world's best medicinal cannabis researchers and clinicians."

Dr Russo said "I'm delighted to be collaborating with Zelda who is at the forefront of efforts to develop plant-derived cannabis medicines that have the potential to improve quality of life for patients. "

Tim Slate
Company Secretary

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics Ltd is an Australian-based bio-pharmaceutical company developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company is undertaking:

- A **human clinical trial programme** focused on insomnia, autism and opioid reduction with activities in Australia and the USA.
- A **pre-clinical research programme** examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline. It has partnered with the world's leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer and cognitive decline.

The Company has also formed a strategic partnership with European medicinal cannabis group HAPA Medical BV, to access HAPA's EU-GMP grade manufacturing capabilities and accessing its German distribution network providing a credible and rapid path to commercialisation for successful clinically validated formulations.

About The ICCI (<https://www.icci.science/en/>)

The International Cannabis and Cannabinoids Institute (ICCI), the first Centre of Excellence in this field located in the heart of Europe - Czech Republic. ICCI identifies, coordinates and supports global research priorities for the advancement of cannabis and cannabinoid treatments through a multidisciplinary, evidence-based approach that incorporates innovative tools and methods.

ICCI combines various institutions (universities, high-tech companies, associations) which consequently provides services to a broad array of entities around the world interested in the development of cannabis and cannabinoids as medicine. These services include; Patient Focused Certification, Consulting, Governmental Relations, Big Data, Plant Research Services, Metabolomic Services, Contract Research Organizations.